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Summary We examined local differences in prescription pattern of home mechanical
ventilation (HMV) within the homogenous health care system in Sweden. We used 6
years prospective data from the national HMV Register covering the entire Swedish
HMV patient population (more than 1000 patients). The treatment prevalence of HMV
in Sweden, January 1, 1996 was 6.2/100,000 and January 1, 2002 10.5/100,000 with a
steady increase each year in all counties. The differences between leading and non-
leading counties showed a tendency to diminish due to an increasing prescription rate
in the non-leading counties. During the 6 years, the proportion of Pickwickian patients
increased significantly in the country as a whole, but remained considerably and
significantly higher in the leading counties, in spite of similar and temporally stable
prescription criteria. Even if the evident dissimilarities in treatment prevalence may
be levelling out, it will most probably do so at a level as high as or higher than today’s
top level of more than 20/100,000 since we found that HMV therapy was well founded
also in the counties with the highest prescription rates and that the prescription rate
of the non-leading counties was approaching the level of the leading counties.










Whereas the criteria, e.g. long-term oxygen ther-
apy in chronic hypoxaemic COPD are well estab-
lished, the criteria for initiating home mechanical
ventilation (HMV) are less well defined.1 There is a
great diversity in the causes of chronic hypoventi-
lation and there is little scientific evidence con-
cerning when to start HMV. Prescription habits may
therefore vary considerably between countries
with different health care systems, as has been
shown in a recent EU survey (JAWedzicha, personal
communication).
In a previous retrospective cross-sectional report,2
we demonstrated considerable inequalities within
Sweden in spite of the generally homogenous health
care system in our country. In this prospective long-
itudinal analysis, we focus on the clinical background
of temporal changes and geographic inequalities in the
prescription of HMV. More specifically, the Pickwickian
group was chosen for detailed analysis, since this
clearly was the most rapidly growing disease category
and had the most variable prescription rates.
Methods
We have previously reported how the Swedish HMV
Register is organized.2 The register is owned by the
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Swedish Society of Chest Medicine and is financially
supported by the National Board of Health and
Welfare. In brief, it collects and works up reports
for all patients from all clinics in Sweden (8.9
million inhabitants) prescribing ventilators for
home use. Annual follow up forms are requested
from the register with reminders sent within 6
months. Since all Swedish citizens have a unique
person identification number, no patient still living
in Sweden can be lost from follow up.
The register forms for those patients who started
HMV before January 1, 1996 contain data on, i.e.
age, sex, primary and secondary diagnoses (pre-
defined groups). For patients starting therapy after
that date, we also have data on blood gases
(spontaneous breathing, room air), vital capacity,
height and weight.
We use the term ‘‘treatment prevalence’’ for the
number of patients (per 100,000 inhabitants) using
a ventilator at a given occasion. The differences in
treatment prevalence for patients of various dis-
ease categories were assessed by chi-square test.
We use the term ‘‘prescription rate’’ for the annual
number (per 100,000 inhabitants) of new ventilator
users. Differences in prescription rates between
groups of counties are analysed with t-test and
changes over time with regression analysis. Values
are expressed as mean and standard deviation (SD).
The Swedish register has been approved by the
Swedish Data Inspection Board and the study has
been approved by the Medical Ethics Committee at
the University of Lund. All patients are given
written information on the register and are
specifically asked by their physicians if they accept
registration.
Results
The treatment prevalence of HMV in Sweden was
6.2/100,000 on January 1, 1996 and 10.5/100,000
on January 1, 2002 with a steady increase each year
(Fig. 1). The annual mortality is low (7–8%) and the
fraction of patients discontinuing ventilation is
typically less than 2%.
There are evident dissimilarities in treatment
prevalence between the 26 counties in Sweden.
The highest treatment prevalence January 1, 1996
was 14/100,000 and has increased to 22/100,000 6
years later, whereas the lowest treatment preva-
lence in the same period has increased from 1 to 4/
100,000. The same four counties (from now on
designated ‘‘leading counties’’, comprising 15% of
the Swedish population), have retained their top
position, with a large gap to the non-leading
counties as shown in Fig. 2. The initial large
difference in prescription rate between the leading
and the non-leading counties has, however, de-
creased and did not reach statistical significance in
2001 (Fig. 3). This equalization is primarily caused
by a highly significant increase (r ¼ 0:3; Po0:001)
in the prescription rate among the non-leading
counties.
The percentual diagnosis distribution of patients
alive on ventilator January 1, 1996 is compared to
January 1, 2002 in Fig. 4. The increased proportion
with Pickwickian syndrome is statistically highly
significant (Po0:001). The age distribution has a
bimodal pattern, and has not changed with time
(Fig. 5).
The percentual diagnosis distribution in leading
vs. non-leading counties is shown in Fig. 6. The
difference for the Pickwickian syndrome is statis-
tically highly significant (Po0:001). When ex-
pressed as number of patients per 100,000
inhabitants, the figures for Pickwickian syndrome
differed with a factor of 3.4. The latter difference
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Figure 1 Annual number of new and active users of HMV
in Sweden.
Figure 2 Cumulated prescriptions (per 100,000 inhabi-
tants, not corrected for deceased patients or ‘‘quitters’’)
of HMV in the four leading counties (FF) vs. the 22
non-leading counties (. . . . .). Error bars denote range
(max–min).
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does, however, not alone account for the large
geographic variations in total prescription rate.
The Pickwickian patients (65% males) were on
average 60 years old (SD 11) and had a BMI of 40 (SD
11). Among these patients 24% had an additional
diagnosis of COPD, and in this subgroup BMI was 35
(SD 6), which is statistically significantly lower
compared to the whole group. Data on apnoea/
hypopnoea index are not available in the register.
Initial blood gases in the Pickwickian patients were
the same for each year during the 6-year period,
and did not differ between leading and non-leading
counties (Table 1). Initial vital capacity was
significantly lower in 2001 than 1996 but did not
differ between leading and non-leading counties.
We have analysed blood gas data and vital capacity
for the other diagnosis groups as well, but found no
temporal or geographic differences.
Discussion
An increased number of patients on HMV has been
demonstrated in other centres and countries.3–5
The present data indicate that, although there is a
slightly increasing recruitment of new patients, the
main reason for the increasing prevalence may be a
low mortality, i.e. a steady state has not been
reached. Treatment is seldom discontinued due to
the patient’s request and even more rarely on the
physician’s initiative. Swedish physicians obviously
see little reason to switch from mechanical
ventilation to CPAP in Pickwickian patients.
It is difficult to estimate at what level the
demand for HMV may be fully met. Our present
data indicate that today’s top levels of 22/100,000
ARTICLE IN PRESS
Figure 3 Annual prescription rate (per 100,000) of HMV
in the four leading counties (FF) vs. the 22 non-leading
counties (. . . . .). Error bars denote SEM (standard error
of the mean). Differences are significant for the years
1996–2000 but not for 2001. Regression line for the non-
leading counties is also drawn, indicating a significant
annual increase (r ¼ 0:3; Po0:001).
Figure 4 Diagnosis distribution of ventilator users
January 1, 1996 (register launching) and December 31,
2001. The increase in the proportion of the Pickwickian
syndrome is highly significant (8% vs. 17%, Po0:001). The
group ‘‘Neuro’’ comprises muscular dystrophy, spinal
muscular atrophy, ALS, dystrophia myotonica, etc., the
group ‘‘Other’’ is very heterogenous, including, e.g.
patients with traumatic tetraplegia and central alveolar
hypoventilation.
Figure 5 Age distribution of ventilator users 1996
(register launching) and 2001.
Figure 6 Diagnosis distribution of ventilator users in
leading counties and non-leading counties. The differ-
ence in the proportion of the Pickwickian syndrome is
highly significant (25% vs. 14%, Po0:001). For further
explanation of ‘‘Neuro’’ and ‘‘Other’’, see Fig. 4.
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are medically justified, since we could show that
counties with high prescription rates had as strict
indications as other counties.
We made a deeper analysis of the Pickwickian
patients due to their particular feature of an
increase in quantity that was higher than any other
patient group and showing the greatest geographic
differences. This may have several explanations.
Enhanced awareness of the symptoms of sleep-
related respiratory disturbances and increased
body weight in the general population are factors
that may contribute. Widening of the indications
seems not to be the case, as shown by our
continuous analysis of the initial blood gas data.
On the other hand, when the Pickwickian patients
had an additional diagnosis of COPD they initiated
ventilation with a lower BMI than the whole group.
An obvious explanation for this is the synergistic
respiratory effect of the two conditions. Unfortu-
nately, the register does not include sufficient lung
function data to evaluate this argument.
The steady increase in the proportion of Pick-
wickian patients and the fact that the leading
counties were leading also for this disease category
indicate that the health care system must be
prepared to meet increasing demands for care of
this heavy patient group.
It is noteworthy that the Swedish treatment
prevalence of HMV for patients with primary lung
diseases is considerably lower than that in many other
European countries (JA Wedzicha, personal commu-
nication). Lower prevalence of smoking-related re-
spiratory insufficiency could theoretically partly
account for this difference. Reluctance of Swedish
chest physicians to initiate ventilator treatment in
COPD patients due to expected high mortality6 and
low patient compliance is another and probably more
plausible explanation. Should a paradigm shift in this
field occur, it may result in a radical increase in the
total number of patients on HMV.
Dissimilarities in treatment prevalence between
nations with different health care systems is to be
expected, irrespective of actual differences in the
prevalence of underlying diseases. Furthermore, from
a global point of view, an international specification
of a medically justified treatment prevalence is likely
to be controversial, as this prevalence is influenced
not only by economy, but by local cultural and
political factors as well. The novel finding in our study
is that large differences may appear within a
homogenous health care system, even if indications
for treatment seem to be uniform. We wish to point
out that the four counties with the highest prescrip-
tion rates have no particular demographic properties
in common. One is entirely urban (Gothenburg),
whereas two are extremely sparsely populated (in
the very north of Sweden). Major economic differ-
ences between Swedish counties are actively coun-
teracted by the state, with a method sometimes
called ‘‘Robin Hood-taxation’’, allocating money from
the rich to the poor counties. The most plausible
explanation for the differences in prescription rate
rests on the individual physicians. We believe that
dedicated clinicians in the four leading counties
started early to identify the target population that
could gain benefit from HMV. However, the non-
leading counties seem to be catching up, since their
prescription rate increases significantly, whereas the
leading counties may have reached a more stable
activity (Fig. 3).
A register-based study may be severely biased in
case of under-reporting. The register receives
reports from 35 clinics, of whom eight are
responsible for two-thirds of the entire registered
population. We cannot claim total coverage of all
small centres in Sweden, but their numerical
contribution to our data would be negligible. Loss
of data from the bigger centres may be a more
significant problem. Therefore, we annually send
out individualized reports to each clinic with a
request for completion of data if necessary.
Telephone calls have also been used to ensure
completeness of data. It is estimated that the
register covers at least 95% of the target popula-
tion. It is extremely rare (approximately 1%) for
patients to refuse participation in the register.
The diagnosis groups are predefined in the
register forms. The Pickwickian group is defined
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Table 1 Lung function and blood gas data (room air, spontaneous breathing) (mean and SD) for Pickwickian









Vital capacity (l) 2.470.9 2.371.0 2.971.0 2.370.9n
PO2 (kPa) 7.471.3 7.671.6 7.371.9 7.871.4
PCO2 (kPa) 7.171.2 7.071.3 7.871.6 7.071.3
nP-values typically 0.5¼NS for all comparisons, except for the difference in VC between 1996 and 2001 where the difference is
significant (Po0:05).
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as obstructive sleep apnoea syndrome (OSAS)
patients with chronic hypoventilation. The register
specifically excludes sleep apnoea/hypopnoea pa-
tients using BilevelPAP only because they do not
tolerate conventional CPAP. Blood gas data confirm
that the material is not influenced by such patients.
However, weight data from the register suggest
that some patients with pure obesity-hypoventila-
tion syndrome not fullfilling criteria for OSAS may
have been classified as ‘‘other diagnosis’’ in the
register.
In conclusion, we have found a medically
justified continuing increase in the number of
patients on HMV and an increasing proportion of
Pickwickian patients. The evident dissimilarities in
local prescription rates are not explained by
different therapeutic criteria between the clinics,
but rather with differences in levels of ambition
and/or problem recognition. There are reasons to
believe that future treatment prevalence on a
national base may exceed today’s local top level at
22/100,000 inhabitants.
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